<DOC>
	<DOCNO>NCT00233961</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect store transplant . PURPOSE : This phase I trial study side effect G-CSF stimulate peripheral stem cell autologous stem cell transplant treat patient chronic phase chronic myeloid leukemia remission .</brief_summary>
	<brief_title>G-CSF Stimulating Peripheral Stem Cells Autologous Stem Cell Transplant Treating Patients With Chronic Phase Chronic Myeloid Leukemia Complete Remission</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility safety harvest adequate number CD34-positive peripheral blood stem cell use filgrastim ( G-CSF ) patient chronic phase chronic myeloid leukemia complete cytogenetic remission . - Determine safety temporarily discontinue treatment imatinib mesylate use G-CSF harvesting procedure , term percentage Philadelphia chromosome ( Ph ) -positive cell stem cell harvest , patient . OUTLINE : Patients receive filgrastim ( G-CSF ) undergo apheresis 5 day . After completion apheresis , patient resume treatment imatinib mesylate study . Patients may later undergo autologous peripheral blood stem cell transplantation , deem necessary . PROJECTED ACCRUAL : A total 20 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myeloid leukemia In complete cytogenetic remission , confirm bone marrow biopsy within past month Has receiving imatinib mesylate ≥ 3 months* NOTE : *Imatinib mesylate hold study harvest procedure No myelofibrosis bone marrow ≥ 3+ Ineligible refuse allogeneic stem cell transplantation PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Adequate hepatic function stem cell transplantation Renal Adequate renal function stem cell transplantation Cardiovascular Adequate cardiovascular function stem cell transplantation Pulmonary Adequate pulmonary function stem cell transplantation Other HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy Chemotherapy More 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery No concurrent surgery Other No concurrent experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>